Antiviral peptide targeting P protein oligomerization: proof of concept for mononegaviruses

J Gen Virol. 2024 Dec;105(12). doi: 10.1099/jgv.0.002062.

Abstract

In Mononegavirales, phosphoproteins (P) are essential polymerase cofactors, forming oligomers and interacting with viral components to facilitate replication. Previous studies have demonstrated that a P-derived peptide (PFr) from the respiratory syncytial virus (RSV), containing the oligomerization domain (OD) and C-terminal domain (CTD), effectively inhibits RSV replication. Here, we extend this approach to paramyxoviruses, including HPIV3, MeV and MuV. Customized PFrs exhibited potent inhibitory effects against their respective viruses, with IC50 values below 100 nM, while showing minimal cytotoxicity. These findings highlight the potential of targeting P oligomerization as a broad-spectrum antiviral strategy for paramyxoviruses and other mononegaviruses.

Keywords: mononegavirus; oligomerization; peptide inhibitors; phosphoprotein.

MeSH terms

  • Animals
  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacology
  • Cell Line
  • Chlorocebus aethiops
  • Humans
  • Mononegavirales / chemistry
  • Mononegavirales / drug effects
  • Mononegavirales / genetics
  • Mononegavirales / metabolism
  • Peptides* / chemistry
  • Peptides* / metabolism
  • Peptides* / pharmacology
  • Phosphoproteins* / chemistry
  • Phosphoproteins* / metabolism
  • Protein Multimerization
  • Viral Proteins / genetics
  • Viral Proteins / metabolism
  • Virus Replication* / drug effects

Substances

  • Antiviral Agents
  • Phosphoproteins
  • Peptides
  • Viral Proteins